Clearside Biomedical, Inc. (CLSDQ) Stock Price & Analysis
Clearside Biomedical, Inc. (CLSDQ) fell 8.82% to USD 0.31 as of June 10, 2026 at 04:37 UTC, according to Nexqual real-time market data.
CLSDQ last closed at USD 0.34; the session ranged USD 0.31–0.31 on volume of 106 shares. Market capitalization is $1.62M, with a 52-week range of USD 0.01–13.5 (PNK). Source: Nexqual, June 10, 2026 at 04:37 UTC.
Key Statistics (as of June 10, 2026 at 04:37 UTC)
| Price | USD 0.31 |
|---|---|
| Change | ▼ 8.82% (down) |
| Previous Close | USD 0.34 |
| Open | USD 0.31 |
| Day Range | USD 0.31 – 0.31 |
| 52-Week Range | USD 0.01 – 13.5 |
| Volume | 106 shares |
| Market Cap | $1.62M |
| Exchange | PNK |
Technical Analysis (CLSDQ)
Nexqual's technical model rates CLSDQ "SELL" based on 3 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:37 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 14.84 (oversold) |
| vs SMA50 | Below (USD 0.31) |
| MACD | -0.03 (negative) |
Analyst Ratings (CLSDQ)
Wall Street analysts rate CLSDQ "None", per Nexqual as of June 10, 2026 at 04:37 UTC.
| Consensus Rating | None |
|---|
Earnings (CLSDQ)
| Next Earnings Date | 2026-05-06 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -1.14 vs est -0.6 ▼ miss |
| 2025-06-30 | USD -0.06 vs est -1.52 ▲ beat |
| 2025-03-31 | USD -1.65 vs est -1.6 ▼ miss |
| 2024-12-31 | USD -1.5 vs est -1.55 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
Financials & Fundamentals (CLSDQ)
| Total Revenue | $3.33M |
|---|---|
| Revenue Growth (YoY) | -80.60% |
| Gross Margin | +88.07% |
| Operating Margin | -3502.49% |
| Profit Margin | +0.00% |
| Current Ratio | 2.98 |
| Total Cash | $6.80M |
| Total Debt | $61.61M |
| Free Cash Flow | $-20.53M |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
Financial Health Score (CLSDQ)
Nexqual rates Clearside Biomedical, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:37 UTC.
| Growth | Critical — Revenue -80% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $7M cash vs $62M debt |
| Cash Flow | Weak — FCF negative: -$21M, burning cash |
| Efficiency | Mixed — No data |
Ownership (CLSDQ)
| Insider Ownership | +12.88% |
|---|---|
| Institutional Ownership | +7.04% |
| Shares Outstanding | 5.23M |
| Float | 4.57M |
| Short % of Float | +2.74% |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
Leadership (CLSDQ)
Clearside Biomedical, Inc. is led by George M. Lasezkay J.D., Pharm.D., Pharma.D. (age 73), Director & Principal Executive Officer, per Nexqual as of June 10, 2026 at 04:37 UTC.
| Director & Principal Executive Officer | George M. Lasezkay J.D., Pharm.D., Pharma.D. (age 73) |
|---|---|
| Senior Vice President of Engineering & Manufacturing | Rafael V. Andino (age 60) |
Major Backers & Investors (CLSDQ)
Notable institutional backers of Clearside Biomedical, Inc. include DRW Securities, LLC, according to Nexqual as of June 10, 2026 at 04:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DRW Securities, LLC | 0.52% |
Source: Nexqual, June 10, 2026 at 04:37 UTC.
From Clearside Biomedical, Inc.'s Latest SEC 10-K Filing (filed 2025-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- We have successfully completed two clinical trials with CLS-AX in participants with neovascular age-related macular degeneration, commonly referred to as wet AMD. 7   CLS-AX (axitinib injectable suspension) CLS-AX, our most advanced product candidate, is our proprietary suspension of the TKI axitinib for suprachoroidal injection delivered via our SCS Microinjector.
- Our Suprachoroidal Space (SCS) Injection Platform Our suprachoroidal injection platform is a novel, patented approach for delivering pharmacotherapy to the back of the eye via the SCS.
- Approximately 20 million individuals in the United States aged 40 and older are affected with AMD, with a global prevalence of 170 million.
- To expand our overall development pipeline, we are looking to selectively partner our proprietary technology for use with novel gene therapies.
Partnerships
- On July 9, 2019, we entered into a worldwide licensing agreement with Aura Biosciences, Inc., or Aura, for the use of our SCS Microinjector to deliver Aura's proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.
- License agreement for commercialization of XIPERE in United States and Canada On October 22, 2019, we entered into a License Agreement with Bausch + Lomb or, as amended, the Bausch License Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| AKTX | Akari Therapeutics Plc | USD 15 | ▼ 0.46% |
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:37 UTC. This page is informational and not investment advice.